Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models.

Brooks HB, Meier TI, Geeganage S, Fales KR, Thrasher KJ, Konicek SA, Spencer CD, Thibodeaux S, Foreman RT, Hui YH, Roth KD, Qian YW, Wang T, Luo S, Torrado A, Si C, Toth JL, Mc Cowan JR, Frimpong K, Lee MR, Dally RD, Shepherd TA, Durham TB, Wang Y, Wu Z, Iversen PW, Njoroge FG.

Sci Rep. 2018 Oct 18;8(1):15458. doi: 10.1038/s41598-018-33453-4.

2.

Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model.

Fales KR, Njoroge FG, Brooks HB, Thibodeaux S, Torrado A, Si C, Toth JL, Mc Cowan JR, Roth KD, Thrasher KJ, Frimpong K, Lee MR, Dally RD, Shepherd TA, Durham TB, Margolis BJ, Wu Z, Wang Y, Atwell S, Wang J, Hui YH, Meier TI, Konicek SA, Geeganage S.

J Med Chem. 2017 Dec 14;60(23):9599-9616. doi: 10.1021/acs.jmedchem.7b01046. Epub 2017 Nov 9.

PMID:
29072452
3.

NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.

García-Carpizo V, Sarmentero J, Han B, Graña O, Ruiz-Llorente S, Pisano DG, Serrano M, Brooks HB, Campbell RM, Barrero MJ.

Sci Rep. 2016 Sep 8;6:32952. doi: 10.1038/srep32952.

4.

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, McCann D, Na S, Parsons SH, Pratt SE, Shih C, Stancato LF, Starling JJ, Tate C, Velasco JA, Wang Y, Ye XS.

Mol Cancer Ther. 2014 Feb;13(2):364-74. doi: 10.1158/1535-7163.MCT-13-0513. Epub 2013 Dec 19.

5.

Basics of Enzymatic Assays for HTS.

Brooks HB, Geeganage S, Kahl SD, Montrose C, Sittampalam S, Smith MC, Weidner JR.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

6.

Mechanism of Action Assays for Enzymes.

Strelow J, Dewe W, Iversen PW, Brooks HB, Radding JA, McGee J, Weidner J.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

7.

Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study.

Foong CS, Sandanaraj E, Brooks HB, Campbell RM, Ang BT, Chong YK, Tang C.

J Biomol Screen. 2012 Oct;17(9):1136-50. Epub 2012 Aug 27.

PMID:
22927677
8.

Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.

Hamdouchi C, Zhong B, Mendoza J, Collins E, Jaramillo C, De Diego JE, Robertson D, Spencer CD, Anderson BD, Watkins SA, Zhang F, Brooks HB.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1943-7.

PMID:
15780638
9.

Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.

Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM.

Biochemistry. 2005 Feb 22;44(7):2293-304.

PMID:
15709742
10.

Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.

Jaramillo C, de Diego JE, Hamdouchi C, Collins E, Keyser H, Sánchez-Martínez C, del Prado M, Norman B, Brooks HB, Watkins SA, Spencer CD, Dempsey JA, Anderson BD, Campbell RM, Leggett T, Patel B, Schultz RM, Espinosa J, Vieth M, Zhang F, Timm DE.

Bioorg Med Chem Lett. 2004 Dec 20;14(24):6095-9.

PMID:
15546737
11.

Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.

Al-awar RS, Ray JE, Hecker KA, Joseph S, Huang J, Shih C, Brooks HB, Spencer CD, Watkins SA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Carr MA, Zhang F.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3925-8.

PMID:
15225699
12.

1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.

Al-awar RS, Ray JE, Hecker KA, Huang J, Waid PP, Shih C, Brooks HB, Spencer CD, Watkins SA, Patel BR, Stamm NB, Ogg CA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Grutsch JL, Joseph S.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3217-20.

PMID:
15149678
13.

Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.

Zhu G, Conner SE, Zhou X, Chan HK, Shih C, Engler TA, Al-Awar RS, Brooks HB, Watkins SA, Spencer CD, Schultz RM, Dempsey JA, Considine EL, Patel BR, Ogg CA, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3057-61.

PMID:
15149644
14.

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

Hamdouchi C, Keyser H, Collins E, Jaramillo C, De Diego JE, Spencer CD, Dempsey JA, Anderson BD, Leggett T, Stamm NB, Schultz RM, Watkins SA, Cocke K, Lemke S, Burke TF, Beckmann RP, Dixon JT, Gurganus TM, Rankl NB, Houck KA, Zhang F, Vieth M, Espinosa J, Timm DE, Campbell RM, Patel BK, Brooks HB.

Mol Cancer Ther. 2004 Jan;3(1):1-9.

15.

Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.

Sanchez-Martinez C, Shih C, Zhu G, Li T, Brooks HB, Patel BK, Schultz RM, DeHahn TB, Spencer CD, Watkins SA, Ogg CA, Considine E, Dempsey JA, Zhang F.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3841-6.

PMID:
14552792
16.

Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.

Sanchez-Martinez C, Shih C, Faul MM, Zhu G, Paal M, Somoza C, Li T, Kumrich CA, Winneroski LL, Xun Z, Brooks HB, Patel BK, Schultz RM, DeHahn TB, Spencer CD, Watkins SA, Considine E, Dempsey JA, Ogg CA, Campbell RM, Anderson BA, Wagner J.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3835-9.

PMID:
14552791
17.

Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.

Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NB, Anderson BD, Campbell RM, Vasudevan V, Lytle ML.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2261-7.

PMID:
12824014
18.

Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.

Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, Brooks HB, Campbell RM, Considine E, Dempsey JA, Faul MM, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA.

J Med Chem. 2003 May 22;46(11):2027-30.

PMID:
12747775
19.

Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.

Zhu G, Conner S, Zhou X, Shih C, Brooks HB, Considine E, Dempsey JA, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1231-5.

PMID:
12657252
20.

Ornithine decarboxylase promotes catalysis by binding the carboxylate in a buried pocket containing phenylalanine 397.

Jackson LK, Brooks HB, Myers DP, Phillips MA.

Biochemistry. 2003 Mar 18;42(10):2933-40.

PMID:
12627959
21.

Altering the reaction specificity of eukaryotic ornithine decarboxylase.

Jackson LK, Brooks HB, Osterman AL, Goldsmith EJ, Phillips MA.

Biochemistry. 2000 Sep 19;39(37):11247-57.

PMID:
10985770
22.

Treasure of the Past: IV: THE STANDARD-CELL COMPARATOR, A SPECIALIZED POTENTIOMETER.

Brooks HB.

J Res Natl Inst Stand Technol. 2000 Oct 1;105(5):755-77. doi: 10.6028/jres.105.059. Print 2000 Sep-Oct.

23.

X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine.

Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ.

Biochemistry. 1999 Nov 16;38(46):15174-84.

PMID:
10563800
24.
25.

Carbon-13 isotope effect studies of Trypanosoma brucei ornithine decarboxylase.

Swanson T, Brooks HB, Osterman AL, O'Leary MH, Phillips MA.

Biochemistry. 1998 Oct 20;37(42):14943-7.

PMID:
9778371
26.
27.

Role of Arg-277 in the binding of pyridoxal 5'-phosphate to Trypanosoma brucei ornithine decarboxylase.

Osterman AL, Brooks HB, Rizo J, Phillips MA.

Biochemistry. 1997 Apr 15;36(15):4558-67.

PMID:
9109665
28.

Five hundred consecutive carotid endarterectomies: emphasis on vein patch closure.

Lawhorne TW Jr, Brooks HB, Cunningham JM.

Cardiovasc Surg. 1997 Apr;5(2):141-4.

PMID:
9212198
29.
30.
31.

Detection of intermediates in tryptophan tryptophylquinone enzymes.

Davidson VL, Brooks HB, Graichen ME, Jones LH, Hyun YL.

Methods Enzymol. 1995;258:176-90. No abstract available.

PMID:
8524149
33.

Perception of quality of life before and after disclosure of trial results: a report from the Program on the Surgical Control of the Hyperlipidemias (POSCH).

Buchwald H, Fitch LL, Matts JP, Johnson JW, Hansen BJ, Stuenkel MR, Brooks HB.

Control Clin Trials. 1993 Dec;14(6):500-10.

PMID:
8119065
35.

Deuterium kinetic isotope effect and stopped-flow kinetic studies of the quinoprotein methylamine dehydrogenase.

Brooks HB, Jones LH, Davidson VL.

Biochemistry. 1993 Mar 16;32(10):2725-9.

PMID:
8448129
36.

Stabilization of thermally labile alkylcobalamins by a haptocorrin from chicken serum.

Brown KL, Brooks HB, Behnke D, Jacobsen DW.

J Biol Chem. 1991 Apr 15;266(11):6737-41.

37.

Determination of fluorocarbon in blood.

Stein TP, Robbins WK, Brooks HB, Wallace HW.

J Biomed Mater Res. 1975 Sep;9(5):479-85.

PMID:
1176521
38.

The use of optical emission spectroscopy for human 15N tracer studies.

Stein TP, Leskiw MJ, Liquori EM, Brooks HB, Wallace HW, Blakemore WS.

Anal Biochem. 1975 Jun;66(2):481-8. No abstract available.

PMID:
1137107

Supplemental Content

Loading ...
Support Center